Key result
Deutetrabenazine ER undergoes evaluation for patient-reported tardive dyskinesia experiences post-valbenazine.
Patient satisfaction may inform switching after valbenazine; leaves open comparative efficacy in tardive dyskinesia.
To explore patient-reported experiences with once-daily (QD) deutetrabenazine extended-release tablets among those with prior valbenazine use (PVU).
No takes yet. Share an insight, caveat, or question.
Jain et al. (2026) studied this question. Once-daily deutetrabenazine extended-release tablets were evaluated for patient-reported experiences in individuals with tardive dyskinesia and prior valbenazine use.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: